Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice
- 1 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (7) , 1297-1302
- https://doi.org/10.1161/01.atv.0000130463.68272.1d
Abstract
Objective—Both the apolipoprotein A5 and C3 genes have repeatedly been shown to play an important role in determining plasma triglyceride concentrations in humans and mice. In mice, transgenic and knockout experiments indicate that plasma triglyceride levels are strongly altered by changes in the expression of either of these 2 genes. In humans, common polymorphisms in both genes have also been associated with plasma triglyceride concentrations. These similar findings raised the issue of the relationship between these 2 genes and altered triglycerides.Methods and Results—To address this issue, we generated independent lines of mice that either overexpressed (“double transgenic”) or completely lacked (“double knockout”) both apolipoprotein genes. We report that both “double transgenic” and “double knockout” mice display normal triglyceride concentrations compared with overexpression or deletion of either gene alone. Furthermore, we find that human ApoAV plasma protein levels in the “double transgenic” mice are ≈500-fold lower than human ApoCIII levels, supporting ApoAV as a potent triglyceride modulator despite its low concentration.Conclusions—Together, these data support thatAPOA5andAPOC3independently influence plasma triglyceride concentrations but in an opposing manner.Keywords
This publication has 27 references indexed in Scilit:
- Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildrenHuman Genetics, 2002
- Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglyceridesHuman Molecular Genetics, 2002
- An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative SequencingScience, 2001
- Families with Familial Combined Hyperlipidemia and Families Enriched for Coronary Artery Disease Share Genetic Determinants for the Atherogenic Lipoprotein PhenotypeAmerican Journal of Human Genetics, 1998
- Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.Journal of Clinical Investigation, 1997
- Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IVScience, 1996
- Association between genetic variation at the APO AI‐CIII‐AIV gene cluster and familial combined hyperlipidaemiaClinical Genetics, 1994
- Automated immunoturbidimetric analysis of six plasma apolipoproteins: Correlation with radial immunodiffusion assaysJournal of Clinical Laboratory Analysis, 1991
- Structure and evolution of the apolipoprotein multigene familyJournal of Molecular Biology, 1986
- Human apolipoprotein A-I--C-III gene complex is located on chromosome 11.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1984